Navigation Links
Serious adverse reactions to smallpox vaccine appear to be limited

There was a low rate of life-threatening adverse reactions to the smallpox vaccine administered to potential first responders to a bioterrorism incident, possibly attributable to rigorous vaccine safety screening and educational programs, according to a study in the December 7 issue of JAMA.

Routine childhood immunization against smallpox in the United States ceased in 1971, according to background information in the article. Although the World Health Organization declared in 1980 that smallpox had been eradicated worldwide, there is concern that smallpox virus may exist outside the World Health Organization−designated repository laboratories and may be used as a bioweapon. Detection of a smallpox case could represent an intentional bioterrorism event requiring an immediate, coordinated response by public health, medical, and law enforcement personnel to control the outbreak and protect the public.

In January 2003, the U.S. Department of Health and Human Services (DHHS) implemented a voluntary civilian smallpox vaccination program, in which vaccine was administered to federal, state, and local volunteers who might be first responders during a bioterrorism event.

Christine G. Casey, M.D., of the Centers for Disease Control and Prevention, Atlanta, and colleagues examined the vaccine safety profile among civilians who received smallpox vaccine between January 24 and October 31, 2003. The researchers evaluated adverse events reported via the Vaccine Adverse Event Reporting System (VAERS) and the Centers for Disease Control and Prevention.

A total of 37,901 volunteers in 55 jurisdictions received at least 1 dose of smallpox vaccine. VAERS received 822 reports of adverse events following smallpox vaccination (overall reporting rate, 217 per 10,000 vaccinees). A total of 590 adverse events (72 percent) were reported within 14 days of vaccination. Nonserious adverse events (n = 722) included multiple signs and symptoms of mild and s elf-limited local reactions. One hundred adverse events (12 percent) were designated as serious, resulting in 85 hospitalizations, 2 permanent disabilities, 10 life-threatening illnesses, and 3 deaths. Among the serious adverse events, 21 cases were classified as myocarditis (inflammation of the muscular tissue of the heart) and/or pericarditis (inflammation of a membrane that surrounds the heart) and 10 as ischemic cardiac events that were not anticipated based on historical data. Two cases of generalized vaccinia (a skin eruption in reaction to vaccination) and 1 case of postvaccinial encephalitis (inflammation of the brain) were detected. No preventable life-threatening adverse reactions, contact transmissions, or adverse reactions that required treatment with vaccinia immune globulin were identified. Serious adverse events were more common among older revaccinees than younger first-time vaccinees.

"The absence of preventable serious adverse reactions provides indirect evidence of effective vaccination screening and education, as well as attentive vaccination site care and monitoring," the authors write.

"This comprehensive smallpox vaccine safety monitoring and response system can serve as an effective model for vaccine campaigns that may occur in response to public health emergencies. Unique aspects included rapid detection, investigation, and response to rare and potentially serious adverse events. Our report highlights the success of education, screening, and clinical investigations and reviews in augmenting a robust safety monitoring system to minimize preventable adverse events. Additional reduction of overall vaccinia adverse events might be achievable through study of cardiac and dermatological risk factors, a better understanding of vaccinia host-pathogen interaction, and development of a less reactogenic vaccinia vaccine," the researchers conclude.


'"/>

Source:JAMA and Archives Journals


Related biology news :

1. Clam embryo study shows pollutant mixture adversely affects nerve cell development
2. Patients can report statins adverse effects on new web site
3. Langerhans cells regulate immune reactions in the skin
4. Nano-keys bind cell receptors and trigger allergic reactions
5. Pilot study successful in taming allergic reactions to food
6. Stopping smallpox in its tracks: A new anti-viral approach
7. Secret of smallpoxs success may lead to bioterror cure
8. LIAI scientists make major finding on potential smallpox treatment
9. Researchers develop new testing methods for potential monkeypox or smallpox outbreak
10. Mice studies illustrate potential of chimp/human antibodies to protect against smallpox
11. Defective immune system response to smallpox vaccine detailed in new study
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic ... permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se ... tumor en 2017, con múltiples sitios previstos a lo largo de ... ... el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se ...
(Date:12/15/2016)... FREMONT, Calif. , Dec. 15, 2016   ... a publicly held genomics technology company, announced today that ... the Listing Qualifications Department of The Nasdaq Stock Market ... the closing bid price of WaferGen,s common stock had ... days.  Accordingly, WaferGen has regained compliance with Listing Rule ...
(Date:12/12/2016)... 12, 2016  Researchers at Trinity College, Dublin, ... by combining the material with Silly Putty. The mixture ... detector able to sense pulse, blood pressure, respiration, ... The research team,s findings were ... here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... ... January 18, 2017 , ... Opal Kelly, a leading producer ... Express, announced the ZEM5310 USB 3.0 FPGA Module, combining a SuperSpeed USB 3.0 ... form factor suitable for prototyping, testing, and production-ready integration. The ZEM5310 USB interface ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... for Clinical Ops Executives 2017 in its continued commitment to the advancement of ... makers to discuss current issues related to clinical trial planning and management. ...
(Date:1/18/2017)... NY (PRWEB) , ... January 18, 2017 , ... Researchers from a new study ... do not fall low enough after prostate cancer treatment, this indicates there is still remaining ... risk of mortality. , “ The PSA test has always been an indicator of whether ...
(Date:1/18/2017)... Shareholder rights law firm Johnson & Weaver, ... members of CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD ... proposed sale of the Company to Eli Lilly and ... molecules for the acute treatment of migraines. ... a definitive merger agreement with Eli Lilly. Under the ...
Breaking Biology Technology: